Compare ILAG & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILAG | AKTX |
|---|---|---|
| Founded | 1981 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9M | 9.1M |
| IPO Year | 2022 | N/A |
| Metric | ILAG | AKTX |
|---|---|---|
| Price | $2.50 | $0.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | 75.6K | ★ 306.2K |
| Earning Date | 12-22-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,338,785.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.04 | $0.22 |
| 52 Week High | $9.80 | $1.73 |
| Indicator | ILAG | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.31 | 44.92 |
| Support Level | $2.40 | $0.23 |
| Resistance Level | $2.74 | $0.27 |
| Average True Range (ATR) | 0.62 | 0.02 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 12.62 | 48.25 |
Intelligent Living Application Group Inc focuses on designing and producing affordable, high-quality locksets and smart security systems. The company offers high-quality mechanical locksets and smart locks to its customers. Its product portfolio comprises various ODM indoor and outdoor locksets, such as deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks, which are marketed through brands like Kambo and Bamberg. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.